Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Assessing Roche’s RoActemra For Hospitalized COVID-19 Patients

An EMA Opinion Is Expected In October

Executive Summary

Three authorized products currently used for arthritis and other conditions have now been filed for approval in Europe for treating people with severe COVID-19.

You may also be interested in...



Coronavirus Notebook: New Deal To Boost Local Vaccine Manufacturing, EU Warns Of RoActemra Shortages

MSF tells G20 leaders to “put your money where your mouth is” on vaccine sharing, the UK is considering whether to vaccinate all 12-15-year olds, and the UK & Australia are to swap excess vaccines.

Coronavirus Notebook: WHO Backs Actemra & Kevzara In COVID-19, German Body Says Remdesivir Has ‘Considerable Added Benefit’

The UK REACT-1 study has shown a threefold reduction in COVID-19 infections in double-vaccinated adults.

Coronavirus Update: Once Written Off, Roche's Actemra Finally Gets EUA In COVID-19

Actemra finally gains an emergency use authorization, Lilly's antibodies withdrawn again amid Delta variant concerns, plus Latin America’s belief in an anti-parasite drug in COVID-19 could soon be punctured.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel